News
Because of the often nonspecific nature of MCL, diagnostic efforts need to be better streamlined to reduce the risk of misdiagnosis.
Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high valuation and future drug risks.
Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that ...
Hosted on MSN4mon
Advances in systemic mastocytosis: Early signs of efficacy for novel drug and new predictive tool to guide patient careSystemic mastocytosis (SM) is characterized by an abnormal accumulation of mast cells, a type of immune ... DeAngelo, MD, Ph.D., Chief of the Division of Leukemia at Dana-Farber, who presented ...
Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers report. The aptamers -- short ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback